NCT07180186

Microbiota and Probiotic Therapy in Ulcerative Colitis Patients

Evaluation of Microbiota and Probiotic Therapy in Ulcerative Colitis Patients

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 70 (actual)
• Sponsor: Tanta University · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This study aimed to evaluate the role of microbiota and probiotics in Egyptian patients with ulcerative colitis.

Detailed description

Inflammatory bowel disease (IBD) is a group of chronic diseases that significantly affects patients' quality of life and is mainly represented by Crohn's disease (CD) and ulcerative colitis (UC). The microbiome is a key contributor to various fundamental aspects of human health, including host metabolism, infection, and the immune response. Changes in microbiome composition have been linked to complex multifactorial diseases, e.g., type 2 diabetes, metabolic syndrome, and non-alcoholic fatty liver syndrome, as well as inflammatory bowel disease (IBD).

Conditions

• Microbiota
• Probiotic Therapy
• Ulcerative Colitis

Interventions

Type	Name	Description
DRUG	Mesalamine	Patients with ulcerative colitis in remission treated with oral mesalamine.
DRUG	Probiotics (Bacillus Clausii)	Patients with ulcerative colitis in remission treated with probiotics (Bacillus Clausii).
DRUG	Mesalamine and probiotics (Bacillus Clausii)	Patients with ulcerative colitis in remission treated with oral mesalamine and probiotics (Bacillus Clausii).

Timeline

• Start date: 2022-01-01
• Primary completion: 2024-05-01
• Completion: 2024-05-01
• First posted: 2025-09-18
• Last updated: 2025-09-18

Locations

1 site across 1 country: Egypt